Top Markets
Coin of the day
HLS Therapeutics Inc. HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS
Rank in Stocks #22602
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Share Price
$2.75
Last synced: 2026-08-21
Market Cap
$86.08M
Change (1 day)
-3.85%
Change (1 year)
-27.06%
Country
CA
Trade HLS Therapeutics Inc. (HLS)

Category

Stock price history for HLS Therapeutics Inc. (HLS)
Highest end of day price: $2.84 on 2026-08-01

Lowest end of day price: $8.95 on 2018-03-01
Stock price history of HLS Therapeutics Inc. from 2018 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -2.32%
2025 38.06%
2024 -5.73%
2023 -63.25%
2022 -36.71%
2021 -13.17%
2020 -7.23%
2019 30.14%
2018 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$171.67 -
DE
$163.63 24.47%
DE
$37.61 20.44%
JP
$223.11 32.20%
CH
$20.99 11.67%
IN